“Partnering with Paige empowers our mission to improve treatment decisions and patient outcomes, ensuring that a larger number of patients benefit from prognostic risk profiling. By integrating Stratipath Breast in the Paige AppLab, clinicians will have easy access to a fast and cost-effective alternative to traditional molecular assays,” said Annica Jämtén Ericsson, COO, Stratipath

“We are excited to welcome these six additional industry-leading digital pathology vendors to the Paige AppLab. Their partnership serves as a testament to the innovative and cutting-edge technology Paige is built upon,” said Jill Sue, Vice President of Product, Paige. “With these vendor additions, the Paige AppLab serves as the one-stop-shop for all digital pathology needs.”